Johnson & Johnson (NYSE:JNJ) on Friday announced topline results from Phase 3b APEX study of Tremfya (guselkumab) in patients with active psoriatic arthritis (PsA) who are biologic naïve and have had ...

This informational guide, part of Popsugar's Condition Center, lays out the realities of this health concern: what it is, what it can look like, and strategies that medical experts say are proven to ...

When the immune system mistakenly attacks healthy cells in both the skin and joints, the result is psoriatic arthritis—a challenging condition that affects approximately 1 million Americans. While ...

Otezla (apremilast) is an oral tablet commonly used to treat psoriatic arthritis in adults. Psoriatic arthritis is a long-lasting condition that affects the joints in people with psoriasis. Common ...

An estimated 3% of the world's population have psoriasis, with approximately 6.4 million people across Europe affected. Almost one third of people with psoriasis will develop psoriatic arthritis (PsA) ...

A Bristol Myers Squibb drug that was first in its class to hit a certain immunological target now has positive data from two pivotal tests in psoriatic arthritis that could support expanding use of ...

The results of 2 recent clinical trials combining the GLP-1 drug and the biologic reinforce the benefits of treating obesity and inflammation together.